Skip to content

(R33 Phase) DELISH Study: Diabetes Education to Lower Insulin, Sugars, and Hunger

Optimizing Lifestyle Interventions With Mindfulness-based Strategies in Type 2 Diabetes

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03837405
Acronym
DELISH R33
Enrollment
125
Registered
2019-02-12
Start date
2018-12-12
Completion date
2021-06-17
Last updated
2026-06-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Brief summary

The investigators plan an R33 phase trial in which 120 persons with type 2 diabetes (T2DM) will be randomized (using a 1:1 ratio) to education alone (Ed) on following a carbohydrate restricted diet for T2DM, or this same education content with added mindful eating/Mindfulness-Based Intervention components (Ed+MBI).

Detailed description

The investigators will randomize 120 persons with T2DM in a 1:1 ratio to a nutrition education alone arm (Ed n=60) vs. a nutrition education with mindfulness-based intervention components (Ed+MBI n=60) arm and follow them for 12 months. The interventions will be provided in a weekly group setting, with about 10 to 12 persons per group. Some educational intervention components will be delivered using a smartphone app. After the 12-week initial intervention, the investigators will re-randomize participants using an adaptive intervention design to receive low, medium, or high intensity maintenance training, depending on level of adherence achieved during the initial intervention period. Follow-up assessments will be performed at 3, 6, 9, and 12 months. The investigators will address the following specific aims: 1. Test the hypothesis that the Ed+MBI arm will have better dietary adherence than the Ed arm. 2. Test whether our proposed behavioral mechanisms (e.g. decreased eating in response to cravings or difficult emotions) predict dietary adherence. 3. Obtain preliminary assessment of intervention effects on clinical outcomes This is the second phase of a two-phase study. Pilot testing has been completed in the first phase (R61). The focus of the second phase (R33) is on comparing dietary adherence between the Ed only and ED + MBI arms over a 12-month period. This phase will also include employing an adaptive intervention design in the post-treatment phase to test optimization of the maintenance intervention (i.e. assigning maintenance intensity/dose based on how a participant is doing). The maintenance phase intensities will be assessed to provide preliminary data for planning future trials. The primary analysis focus of this phase will be on the comparing the groups formed by the initial randomization to Ed versus Ed + MBI. The investigators will use fingerstick blood ketone measures, which provide an objective measure of whether the target levels of carbohydrate restriction have been attained, as our primary adherence outcome measure. This will be supplemented by 24-hour diet recall measures of carbohydrate consumption. Important secondary outcome measures will include clinical measures such as glycosylated hemoglobin and behavioral measures such as frequency of eating in response to food cravings.

Interventions

Education for carbohydrate-restricted diet

BEHAVIORALMindfuless

Mindful eating app use plus group sessions to learn mindfulness

Sponsors

University of California, San Francisco
Lead SponsorOTHER
National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Masking description

Blood tests at LabCorp and 24-hour dietary recall interviews are done by research assistants blinded to treatment assignment.

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. History of T2DM mellitus. 2. HbA1c ≥ 6.5% and \< 12.0% at screening. 3. Experience food-related cravings most days of the week and eat in response to these cravings regularly. 4. Aged 18 years old and older. 5. Able to engage in light physical activity. 6. Willing and able to participate in the interventions including appropriate participation in the group setting. 7. Have smartphone and are willing to use it on a regular basis for data collection. 8. Ability to speak English.

Exclusion criteria

1. Unable to provide informed consent. 2. A substance abuse, mental health, or medical condition that, in the opinion of investigators, will make it difficult for the potential participant to participate in the intervention, that may need immediate changes in medical management that will affect study outcome measures, or that may require important adaptations in the study diet. 3. Pregnant or planning to get pregnant in the next 12 months, breastfeeding or less than 6 months post-partum. 4. Current use of weight loss medications, such as Alli or amphetamine-based drugs that may affect weight. 5. Planned or history of weight-loss (bariatric) surgery, or other intestinal surgeries that cause malabsorption. These are likely to change study outcome measures, making it difficult to distinguish the effects of the intervention program, or require extensive tailoring of the diet intervention. 6. Currently enrolled in a weight loss program, such as Weight Watchers or a self-help group such as Overeaters Anonymous, or have unalterable plans to enroll in one of these programs in the next year; using a ketogenic low carbohydrate diet in the past 6 months with advice from a health care professional; or use of a mindful eating program with guidance from a professional in the past 6 months or have ever used the study mindful-eating app. 7. Vegan or vegetarian. 8. Unwilling to do regular blood testing at home for glucose or ketone monitoring.

Design outcomes

Primary

MeasureTime frameDescription
Diet Adherence Between Intervention Arms as Measured by % of Ketones >= 0.5 mmol/LMeasures from ketone measure initiation (week 5) to 12 months. Ketones were measured daily over 7 days at 5 study timepoints: 5 weeks, 3, 6, 9, and 12 months.Percent of participant ketone measures \> or = 0.5 mmol/L during trial, by study arm
Diet Adherence Between Intervention Arms as Measured by % of Participants in Each Arm With < 50 Grams/Day of Non-fiber Carbohydrate on 24- Hour Diet RecallAverage of three measures, done at 3, 6 and 12 monthsAverage percent of participant measures with consumption of \< 50 grams/day of non-fiber carbohydrate (from 24-hour diet recall) by arm. Each participant was assigned a % of up to three measures reporting \< 50 grams/day of non-fiber carbohydrate consumption, and this percent was averaged across each arm.

Secondary

MeasureTime frameDescription
Emotion-related Eatingchange from baseline to 12 monthschange in emotion-related eating as measured by the Coping subscale of the Palatable Eating Motives Scale (PEMS). The coping subscale ranges from 1 to 5 (based on a mean of 4 items), with higher values indicating more emotion-related eating (the intervention aimed to lower this score--lower scores represent improvement).
Glycemic Control--HbA1cchange from baseline to 12 monthsChange in Hemoglobin A1c from baseline to 12 months with study arm
Frequency of Eating in Response to CravingsChange from baseline to 12 monthsFrequency of eating in response to cravings (indulgence) using ecological momentary assessment (EMA), operationalized as the percent of solicited occasions when a participant reported eating in response to cravings (rather than in response merely to hunger). Participants received 18 queries about eating in response to cravings over 3 days. Participants had to respond to at least 9 queries to have adequate data completeness for analysis. Frequency of eating in response to cravings is the proportion (scaled as a percent) of queries that participants responded to with responses that reported eating in response to cravings.
Diet Adherence Between Intervention Arms as Measured by Mean Grams of Non-fiber Carbohydrate Consumed Per Day From 24- Hour Diet RecallFrom 3 to 12 months, using measures done at 3, 6, and 12 monthsMean grams of non-fiber carbohydrate consumed per day (from 24-hour diet recall) during trial. We calculated average grams of non-fiber consumed per day across up to three measures during the trial for each participant, and this was averaged across arms.
Salzburg Stress Eating Scalechange from baseline to 12 monthsChange in stress-related eating as measured by Salzburg Stress Eating Scale. Range is from 1 to 5. Higher scores indicate greater stress-related eating.
Weight Changechange from baseline to 12 month weight dataBody mass in kilograms (kg) from baseline to 12 months

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORRick Hecht, MD

University of California, San Francisco

PRINCIPAL_INVESTIGATORElissa Epel, PhD

University of California, San Francisco

Baseline characteristics

Characteristic
Age, Continuous58.4 years
STANDARD_DEVIATION 10.1
Hemoglobin A1c8.54 % of hemaglobin with glycosolation
STANDARD_DEVIATION 1.5
Race/Ethnicity, Customized
Asian or Pacific Islander
11 Participants
Race/Ethnicity, Customized
Black
14 Participants
Race/Ethnicity, Customized
Latino/a
10 Participants
Race/Ethnicity, Customized
Native American
0 Participants
Race/Ethnicity, Customized
Other or more than one
4 Participants
Race/Ethnicity, Customized
White
27 Participants
Region of Enrollment
United States
63 participants
Sex: Female, Male
Female
40 Participants
Sex: Female, Male
Male
22 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
EG002
affected / at risk
EG003
affected / at risk
EG004
affected / at risk
EG005
affected / at risk
EG006
affected / at risk
EG007
affected / at risk
EG008
affected / at risk
EG009
affected / at risk
EG010
affected / at risk
EG011
affected / at risk
deaths
Total, all-cause mortality
0 / 630 / 620 / 151 / 150 / 150 / 150 / 150 / 140 / 140 / 160 / 21 / 4
other
Total, other adverse events
24 / 6325 / 628 / 158 / 1513 / 156 / 158 / 157 / 148 / 147 / 160 / 20 / 4
serious
Total, serious adverse events
0 / 630 / 620 / 150 / 150 / 150 / 150 / 150 / 140 / 140 / 160 / 20 / 4

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 18, 2026